Kenneth I. Moch Chimerix President and CEO
His management of Alteon was memorable as a failure.
as ceo of this company his claim to fame was filling grievances against Siga because they filed the Smallpox vaccine program under the small business enterprise application even though the ceo of Revlon is involved with Siga
Kenneth Moch joined Chimerix in 2009 as Chief Operating Officer and was named President and CEO in April 2010. He brings more than 30 years of experience in managing and financing biomedical technologies, having played a key role in building several life science companies. Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services to life sciences companies, where he most recently served as President and CEO of BioMedical Enterprises, Inc. Previously, he was Managing Director, Healthcare Investment Banking, at ThinkEquity Partners. From 1998 to 2005, Mr. Moch served as President and CEO of Alteon Inc., a biotechnology company specializing in small molecule therapeutics for cardiovascular aging and diabetic complications, having joined in 1995 as SVP, Finance and Business Development & CFO. As President and CEO of the cellular therapy company Biocyte Corporation, Mr. Moch pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell bank. Previously, he was a co-founder and Vice President of The Liposome Company, Inc., and a management consultant with McKinsey & Company, Inc.
Mr. Moch is a past Chairman of the Biotechnology Council of New Jersey and currently serves on the Emerging Companies Section Governing Board of the Biotechnology Industry Organization. He is a member of the Board of Directors of M2Gen/Moffitt Genetics Corporation, a for-profit partnership between Merck and the H. Lee Moffitt Cancer & Research Institute. Mr. Moch holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.
